{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:28:28Z","timestamp":1791912508555,"version":"4.3.4"},"reference-count":94,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2010,4,12]],"date-time":"2010-04-12T00:00:00Z","timestamp":1271030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:p><jats:bold>Background:\u2002<\/jats:bold> Important progress has been made in our understanding of the autoimmune neuromuscular transmission (NMT) disorders; myasthenia gravis (MG), Lambert\u2013Eaton myasthenic syndrome (LEMS) and neuromyotonia (Isaacs\u2019 syndrome).<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> To prepare consensus guidelines for the treatment of the autoimmune NMT disorders, references retrieved from MEDLINE, EMBASE and the Cochrane Library were considered and statements prepared and agreed on by disease experts.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Anticholinesterase drugs should be given first in the management of MG, but with some caution in patients with MuSK antibodies (good practice point). Plasma exchange is recommended in severe cases to induce remission and in preparation for surgery (recommendation level B). IvIg and plasma exchange are effective for the treatment of MG exacerbations (recommendation level A). For patients with non\u2010thymomatous MG, thymectomy is recommended as an option to increase the probability of remission or improvement (recommendation level B). Once thymoma is diagnosed, thymectomy is indicated irrespective of MG severity (recommendation level A). Oral corticosteroids are first choice drugs when immunosuppressive drugs are necessary (good practice point). When long\u2010term immunosuppression is necessary, azathioprine is recommended to allow tapering the steroids to the lowest possible dose whilst maintaining azathioprine (recommendation level A). 3,4\u2010Diaminopyridine is recommended as symptomatic treatment and IvIG has a positive short\u2010term effect in LEMS (good practice point). Neuromyotonia patients should be treated with an antiepileptic drug that reduces peripheral nerve hyperexcitability (good practice point). For paraneoplastic LEMS and neuromyotonia optimal treatment of the underlying tumour is essential (good practice point). Immunosuppressive treatment of LEMS and neuromyotonia should be similar to MG (good practice point).<\/jats:p>","DOI":"10.1111\/j.1468-1331.2010.03019.x","type":"journal-article","created":{"date-parts":[[2010,4,12]],"date-time":"2010-04-12T10:38:21Z","timestamp":1271068701000},"page":"893-902","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":341,"title":["Guidelines for treatment of autoimmune neuromuscular transmission disorders"],"prefix":"10.1111","volume":"17","author":[{"given":"G. O.","family":"Skeie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Apostolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Evoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. E.","family":"Gilhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Illa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Harms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hilton\u2010Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Melms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. W.","family":"Horge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,21]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2004.00867.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri916"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880171208"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1990.tb05440.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410320419"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.3109\/08916939509001933"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.1999.650555.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197611020-00002"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10018"},{"key":"e_1_2_6_11_2","first-page":"341","article-title":"Treatment of severe myasthenia gravis with cyclosporin. A 12\u2010month open trial","volume":"18","author":"Goulon M","year":"1989","journal-title":"Presse Med"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2005.072355"},{"key":"e_1_2_6_13_2","first-page":"145","article-title":"Air\u2010flow limitation in myasthenia gravis. The effect of acetylcholinesterase inhibitor therapy on air\u2010flow limitation","volume":"130","author":"Szathmary I","year":"1984","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_6_14_2","first-page":"618","article-title":"Air\u2010flow limitation in myasthenia gravis. The effect of acetylcholinesterase inhibitor therapy on air\u2010flow limitation","volume":"128","author":"Shale DJ","year":"1983","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20515"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00833919"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/088307389601100608"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(93)90025-I"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2008.09.033"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.57.11.1596"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70063-8"},{"key":"e_1_2_6_22_2","first-page":"CD002275","article-title":"Plasma exchange for myasthenia gravis","volume":"4","author":"Gajdos P","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_23_2","first-page":"939","article-title":"Long\u2010term effects of plasma exchange in myasthenia. Results of a randomized study","volume":"12","author":"Gajdos P","year":"1983","journal-title":"Presse Med"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)92294-3"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02246.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B"},{"key":"e_1_2_6_27_2","first-page":"CD002277","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"1","author":"Gajdos P","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_28_2","first-page":"CD002277","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"2","author":"Gajdos P","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410615"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000256698.69121.45"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2008.11.040"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-197610000-00008"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-002-0037-x"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.1.7"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn092"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2003.00209.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awg223"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2009.02.021"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(200010)48:4<603::AID-ANA6>3.0.CO;2-1"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10665"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410150316"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-200406000-00008"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.6.1778"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410150615"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(97)05370-7"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10133"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(00)00192-2"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198703193161205"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/0896-8411(92)90048-U"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1993.tb22937.x"},{"key":"e_1_2_6_51_2","first-page":"211","article-title":"Results of a one\u2010year open trial of cyclosporine in ten patients with severe myasthenia gravis","volume":"20","author":"Goulon M","year":"1988","journal-title":"Transplant Proc"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050141"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.3.448"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.1.97"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.1.94"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1159\/000050768"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.3.912-a"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004691-200309000-00011"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4598(200008)23:8<1287::AID-MUS22>3.0.CO;2-L"},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000094122.88929.0B"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000312374.95186.cc"},{"key":"e_1_2_6_62_2","doi-asserted-by":"crossref","first-page":"22992","DOI":"10.1016\/S0021-9258(19)49416-7","article-title":"The calcium release channel of sarcoplasmic reticulum is modulated by FK\u2010506\u2010binding protein. Dissociation and reconstitution of FKBP\u201012 to the calcium release channel of skeletal muscle sarcoplasmic reticulum","volume":"268","author":"Timerman AP","year":"1993","journal-title":"J Biol Chem"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000125254.99397.68"},{"key":"e_1_2_6_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10472"},{"key":"e_1_2_6_65_2","doi-asserted-by":"publisher","DOI":"10.1054\/jocn.2001.0907"},{"key":"e_1_2_6_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2006.03.010"},{"key":"e_1_2_6_67_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.47.0513"},{"key":"e_1_2_6_68_2","doi-asserted-by":"publisher","DOI":"10.1067\/S0022-3476(03)00300-7"},{"key":"e_1_2_6_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.04.039"},{"key":"e_1_2_6_70_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02399.x"},{"key":"e_1_2_6_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2009.02.357"},{"key":"e_1_2_6_72_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.9.1732"},{"key":"e_1_2_6_73_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100034077"},{"key":"e_1_2_6_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2007.01.001"},{"key":"e_1_2_6_75_2","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0003-9993(23)00011-4","article-title":"Physical training effects in myasthenia gravis","volume":"74","author":"Lohi EL","year":"1993","journal-title":"Arch Phys Med Rehabil"},{"key":"e_1_2_6_76_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000082725.21444.EC"},{"key":"e_1_2_6_77_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02689.x"},{"key":"e_1_2_6_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92652-6"},{"key":"e_1_2_6_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2005.01.002"},{"key":"e_1_2_6_80_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.3.447"},{"key":"e_1_2_6_81_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.58.1.85"},{"key":"e_1_2_6_82_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.73.6.766"},{"key":"e_1_2_6_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2004.10.018"},{"key":"e_1_2_6_84_2","first-page":"CD003279","article-title":"Treatment for Lambert\u2010Eaton myasthenic syndrome","volume":"2","author":"Maddison P","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_85_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198912073212303"},{"key":"e_1_2_6_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)76153-5"},{"key":"e_1_2_6_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01266.x"},{"key":"e_1_2_6_88_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf178"},{"key":"e_1_2_6_89_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410215"},{"key":"e_1_2_6_90_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/116.2.453"},{"key":"e_1_2_6_91_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/124.12.2417"},{"key":"e_1_2_6_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(00)00407-X"},{"key":"e_1_2_6_93_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410380505"},{"key":"e_1_2_6_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0303-8467(00)00093-7"},{"key":"e_1_2_6_95_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2000.102004271.x"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1331.2010.03019.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1331.2010.03019.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T19:06:02Z","timestamp":1698692762000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1331.2010.03019.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,21]]},"references-count":94,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1111\/j.1468-1331.2010.03019.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03019.x","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,21]]},"assertion":[{"value":"2010-06-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}